

Patents available for licensing and collaborations

Pedro García González

Broad-spectrum bactericidal murein-hydrolases (enzybiotics).

CSIC and CIBERES have developed a polypeptide that allows building new lytic enzymes with improved bactericidal activity and broad spectrum of action. This helps to obtain new pharmaceutical compositions for treating infections caused by pneumococcus and other Gram-positive and Gram-negative bacteria. Enterprises are sought to use the technology under patent license.

[More information](#)

Paloma López García

Obtaining an exopolysaccharide with antiviral action in fish species using bacteria.

CSIC and Valencia University have developed an enzymatic procedure to obtain an exopolysaccharide from lactic bacteria, in particular of the genus *Lactobacillus*. The exopolysaccharide obtained shows antiviral action against viruses that affect fish species, such as salmonids. This exopolysaccharide can be employed in the prevention or treatment of viral infections of these species as food additive and/or in development of pharmaceutical and veterinary products. Enterprises are sought to further develop and use the technology under patent license.

[More information](#)

Ana Martinez Gil

Isatins valid for the treatment of neurodegenerative, inflammatory and autoimmune diseases.

CSIC has synthesized a family of differently substituted isatins exhibiting inhibitory activity of the protein leucine-rich repeat kinase 2 (LRRK2) with application in the treatment of inflammatory, autoimmune and neurodegenerative diseases mediated by this enzyme. Pharmaceutical companies interested in a patent license are sought for.

[More information](#)

Ana Martinez Gil

Benzothiazole Derivatives as CK-1 Inhibitors for the Treatment of Amyotrophic Lateral Sclerosis

CSIC has synthesized a family of benzothiazoles which acts as casein kinase 1 (CK-1) inhibitors. Therefore, these compounds are useful for the treatment of diseases related to circadian rhythm and neurodegenerative, inflammatory, autoimmune, neurological and psychiatric diseases where CK-1 is relevant. Furthermore, these compounds induce cell regeneration. Pharmaceutical companies interested in a patent license are sought for.

[More information](#)

Rafael Giraldo Suárez

Bacterial system for diagnosis and therapy of amyloid proteinopathies

CSIC has developed an efficient bacterial system for *in vivo* identification of amyloidogenic peptides and inhibitors of amyloid protein aggregation. This system can be applied in the diagnosis and therapy of amyloid proteinopathies. Interested companies are sought for implementing and commercializing the new screening technology under patent license agreement

[More information](#)

Ana Martinez Gil

Phenothiazine derivatives for the treatment of autism and syndrome fragile X

CSIC has synthesized group of phenothiazine derivative compounds having activity in the interaction of Ric8 and NCS-1 proteins which are involved in the synaptogenesis process. Therefore, these compounds have application in diseases of the central nervous system that have abnormalities in synapses such as autism and Fragile X. Pharmaceutical companies interested in a patent license are sought for.

[More information](#)